Robert Smith of Pricefx looks at how a sector that is not traditionally price-driven can cope in a world of price volatility
CDMO Hovione used CPhI Worldwide 2021 in Milan to announce plans to invest $170 million over the years 2020-2022 to expand both capacities and capabilities at three sites in Portugal, Ireland, and New Jersey. About 300 jobs will be created as a result.
Following a detailed review, Johnson Matthey has concluded that the potential returns from its Battery Materials business “will not be adequate to justify further investment”. It will therefore seek to sell all or parts of the business.
Flamma USA, the North American arm of the Italian CDMO, has completed the re-commissioning of the HPAPI suite at its site at Malvern, Pennsylvania, following an “exhaustive qualification” over the past six months.
At CPhI Worldwide 2021 in Milan on 9-11 November, Italian CDMO Olon announced “a significant expansion of its pipeline of APIs, a result of its R&D investment strategy”.
Indian chlor-alkali producer Meghmani Finechem is to spend €21.6 million to expand into the chlorotoluene value chain at its site in Dahej, Gujarat.
AGC is to expand the production lines of its AGC Wakasa Chemicals subsidiary at the Kaminaka plant in Japan’s Fukui prefecture.
Arxada, the former Lonza Specialty Ingredients (LSI), has agreed to merge with Troy Corporation in a move that will make a major force in antimicrobials.
Current Issue
CDMO CordenPharma is planning to invest heavily in all its platforms in terms of both capacities and capabi
Advent International, one of the world’s largest private equity investors, has agreed to buy Netherlands-ba
German- and Swiss-based CABB Group is to create a new unified organisation called ‘One CABB’.
Distributor IMCD has agreed to acquire Megasetia Agung Kimia, which it said “provides a significant platfor
Most Popular
The European Chemicals Agency (ECHA) and the European Commission have announced plans to help EU member states and industry to address disinfectant shortages caused by the Covid-19 pandemic.
In a pre-close trading update for the financial year ended 31 March 2021, Johnson Matthey (JM) CEO Robert MacLeod revealed that: “We have commenced a strategic review of Health, as we continue to focus resources to maximise value for our shareholders”.
Full results will be announced on 27 May but it is known that Health, which offers API custom manufacturing services, controlled substances, catalysts and generics, generated sales of £223 million, about 5% of the total sale. The division’s full-year operating performance is expected to be above the prior year.
Roger-Marc Nicoud, CEO of Ypso-Facto, looks at the challenges and opportunities for CDMOs in the current crisis*
The current crisis has highlighted the dependence of European and, indeed, North American countries on delocalised production. This is the case for many goods, including APIs and drugs in general.
